Venture capital raised: $70 million
Avedro raised $70 million during its IPO in Q1 of 2019, according to the MoneyTree report.
Avedro is an ophthalmic medtech company that makes devices to treat corneal ectatic disorders and improve vision to reduce dependency on eyeglasses or contact lenses. The single-use drug formulations are designed to strengthen corneal tissues.
Glaukos ended up purchasing the company in November for an undisclosed amount.